AR090945A1 - Moduladores de la via del complemento y usos de los mismos - Google Patents
Moduladores de la via del complemento y usos de los mismosInfo
- Publication number
- AR090945A1 AR090945A1 ARP130101533A ARP130101533A AR090945A1 AR 090945 A1 AR090945 A1 AR 090945A1 AR P130101533 A ARP130101533 A AR P130101533A AR P130101533 A ARP130101533 A AR P130101533A AR 090945 A1 AR090945 A1 AR 090945A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- cra2
- halogen
- hydrogen
- Prior art date
Links
- 230000000295 complement effect Effects 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 7
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 150000002367 halogens Chemical group 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 5
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 229910052717 sulfur Inorganic materials 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- -1 hydroxy, amino Chemical group 0.000 abstract 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical group O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261642798P | 2012-05-04 | 2012-05-04 | |
| US201361782820P | 2013-03-14 | 2013-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR090945A1 true AR090945A1 (es) | 2014-12-17 |
Family
ID=48626502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130101533A AR090945A1 (es) | 2012-05-04 | 2013-05-06 | Moduladores de la via del complemento y usos de los mismos |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP2855456B1 (enExample) |
| JP (1) | JP6180514B2 (enExample) |
| KR (1) | KR20150003903A (enExample) |
| CN (1) | CN104603127B (enExample) |
| AP (1) | AP2014008040A0 (enExample) |
| AR (1) | AR090945A1 (enExample) |
| AU (1) | AU2013255470B2 (enExample) |
| BR (1) | BR112014027359A2 (enExample) |
| CA (1) | CA2872000A1 (enExample) |
| CL (1) | CL2014002919A1 (enExample) |
| CR (1) | CR20140508A (enExample) |
| EA (1) | EA027113B1 (enExample) |
| ES (1) | ES2630079T3 (enExample) |
| HK (1) | HK1206017A1 (enExample) |
| IL (1) | IL235362A0 (enExample) |
| MX (1) | MX2014013428A (enExample) |
| PE (1) | PE20150623A1 (enExample) |
| PH (1) | PH12014502462A1 (enExample) |
| PL (1) | PL2855456T3 (enExample) |
| PT (1) | PT2855456T (enExample) |
| SG (1) | SG11201406973PA (enExample) |
| TN (1) | TN2014000449A1 (enExample) |
| TW (1) | TW201348199A (enExample) |
| UY (1) | UY34781A (enExample) |
| WO (1) | WO2013164802A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9475806B2 (en) | 2013-03-14 | 2016-10-25 | Novartis Ag | Complement factor B inhibitors and uses there of |
| JO3425B1 (ar) * | 2013-07-15 | 2019-10-20 | Novartis Ag | مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b |
| EP3089963A1 (en) * | 2013-10-30 | 2016-11-09 | Novartis AG | 2-benzyl-benzimidazole complement factor b inhibitors and uses thereof |
| CN103755622A (zh) * | 2013-12-25 | 2014-04-30 | 华东理工大学 | 合成4,5,6,7-四氘代吲哚-3-乙酸的方法 |
| WO2017035408A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Compounds for treatment of immune and inflammatory disorders |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| TWI747873B (zh) | 2016-02-01 | 2021-12-01 | 美商百歐克斯製藥公司 | 苯并吡唑化合物及其類似物 |
| MX2018016046A (es) | 2016-06-27 | 2019-05-02 | Achillion Pharmaceuticals Inc | Quinazolina y compuestos indol para tratar trastornos medicos. |
| CA3053818A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders |
| TWI873092B (zh) | 2018-04-06 | 2025-02-21 | 美商百歐克斯製藥公司 | 取代的苯并呋喃、苯并吡咯、苯并噻吩及結構相關的補體抑制劑 |
| EP3841086B1 (en) | 2018-08-20 | 2025-04-23 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement factor d medical disorders |
| JP7443375B2 (ja) | 2018-09-06 | 2024-03-05 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 医学的障害の治療のための大環状化合物 |
| WO2020051538A1 (en) | 2018-09-06 | 2020-03-12 | Achillion Pharmaceuticals, Inc. | Morphic forms of complement factor d inhibitors |
| WO2020069024A1 (en) | 2018-09-25 | 2020-04-02 | Achillion Pharmaceuticals, Inc. | Morphic forms of complement factor d inhibitors |
| MX2021011507A (es) | 2019-03-22 | 2021-12-15 | Achillion Pharmaceuticals Inc | Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento. |
| JP2023515073A (ja) | 2020-02-20 | 2023-04-12 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 補体因子ｄ媒介障害の処置用のヘテロアリール化合物 |
| CN115702024A (zh) | 2020-04-07 | 2023-02-14 | Ucb生物制药有限责任公司 | 用作il-17调节剂的二氟环己基衍生物 |
| KR20230049115A (ko) * | 2020-08-07 | 2023-04-12 | 상하이 메이유에 바이오테크 디벨롭먼트 컴퍼니 리미티드 | 보체 인자 b 억제제 및 이의 약학적 조성물, 제조 방법 및 용도 |
| CN114057692B (zh) | 2020-08-07 | 2023-07-21 | 上海美悦生物科技发展有限公司 | 一种杂环类化合物、其制备方法及用途 |
| CA3193488A1 (en) | 2020-09-23 | 2022-03-31 | Jason Allan Wiles | Pharmaceutical compounds for the treatment of complement mediated disorders |
| PE20250114A1 (es) * | 2021-06-03 | 2025-01-16 | Chinook Therapeutics Inc | Compuestos indol sustituidos y metodos de uso de los mismos |
| EP4471021A4 (en) | 2022-01-26 | 2025-04-30 | Shanghai Meiyue Biotech Development Co., Ltd. | Salt type and crystal form of complement factor b inhibitor, and preparation method therefor and application thereof |
| WO2023187715A1 (en) * | 2022-04-01 | 2023-10-05 | Novartis Ag | Complement factor b inhibitors and uses thereof |
| CN118026998A (zh) | 2022-11-11 | 2024-05-14 | 上海医药工业研究院有限公司 | 哌啶取代的苯甲酸类化合物、其药物组合物和应用 |
| WO2024141011A1 (zh) * | 2022-12-31 | 2024-07-04 | 深圳晶泰科技有限公司 | 补体因子b抑制剂及其药物组合物和应用 |
| EP4739390A1 (en) | 2023-07-04 | 2026-05-13 | Sitala Bio Ltd | 2-(1h-indol-4-yl)methyl)2h-indazole derivatives as factor b inhibitors |
| CN121752557A (zh) | 2023-07-04 | 2026-03-27 | 希塔拉生物有限公司 | 2-(1h-吲哚-4-基)甲基)-异吲哚啉衍生物作为因子b抑制剂 |
| WO2025008517A1 (en) | 2023-07-06 | 2025-01-09 | Sitala Bio Ltd | Indole derivatives with factor b inhibitory activity |
| WO2025008516A2 (en) | 2023-07-06 | 2025-01-09 | Sitala Bio Ltd | Novel compounds |
| CN119371402A (zh) | 2023-07-26 | 2025-01-28 | 上海美悦生物科技发展有限公司 | 螺环烯基类或氮杂烯基类化合物及其药物组合物、制备方法和用途 |
| WO2025172535A1 (en) | 2024-02-15 | 2025-08-21 | Sitala Bio Ltd | Indole and benzimidazole compounds as factor b inhibitors |
| GB202500206D0 (en) | 2025-01-08 | 2025-02-19 | Sitala Bio Ltd | Novel compounds |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| GB8420919D0 (en) * | 1984-08-17 | 1984-09-19 | Beecham Group Plc | Compounds |
| DE19545464A1 (de) * | 1995-12-06 | 1997-06-12 | Bayer Ag | Benzimidazol-isoindoleninfarbstoffe |
| NZ520028A (en) * | 2000-01-17 | 2004-07-30 | Teijin Ltd | Benzimidazole derivatives |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| GB0400781D0 (en) * | 2004-01-14 | 2004-02-18 | Novartis Ag | Organic compounds |
| KR20070101216A (ko) * | 2004-10-08 | 2007-10-16 | 쉐링 코포레이션 | 트롬빈 수용체 길항제 |
| WO2007034277A1 (en) * | 2005-09-19 | 2007-03-29 | Pfizer Products Inc. | Aryl substituted imidazo [4,5-c] pyridine compounds as c3a receptor antagonists |
| WO2008003703A1 (en) * | 2006-07-03 | 2008-01-10 | Biovitrum Ab (Publ) | Indoles as 5-ht6 modulators |
| JO3265B1 (ar) * | 2008-12-09 | 2018-09-16 | Novartis Ag | مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض |
| JP5819730B2 (ja) * | 2008-12-22 | 2015-11-24 | ケモセントリックス，インコーポレイティド | Ｃ５ａＲアンタゴニスト |
| MX2011008674A (es) * | 2009-02-18 | 2011-11-04 | Amgen Inc | Compuestos de indol/bencimidazol como inhibidores de quinasa mtor. |
| EP2447263A1 (en) * | 2010-09-27 | 2012-05-02 | Bioprojet | Benzazole derivatives as histamine H4 receptor ligands |
| US8846656B2 (en) * | 2011-07-22 | 2014-09-30 | Novartis Ag | Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators |
-
2013
- 2013-05-03 SG SG11201406973PA patent/SG11201406973PA/en unknown
- 2013-05-03 JP JP2015509561A patent/JP6180514B2/ja not_active Expired - Fee Related
- 2013-05-03 HK HK15106552.0A patent/HK1206017A1/xx unknown
- 2013-05-03 CA CA2872000A patent/CA2872000A1/en not_active Abandoned
- 2013-05-03 BR BR112014027359A patent/BR112014027359A2/pt not_active IP Right Cessation
- 2013-05-03 PE PE2014001943A patent/PE20150623A1/es not_active Application Discontinuation
- 2013-05-03 MX MX2014013428A patent/MX2014013428A/es unknown
- 2013-05-03 EA EA201492023A patent/EA027113B1/ru not_active IP Right Cessation
- 2013-05-03 TW TW102115970A patent/TW201348199A/zh unknown
- 2013-05-03 UY UY0001034781A patent/UY34781A/es not_active Application Discontinuation
- 2013-05-03 CN CN201380035327.6A patent/CN104603127B/zh not_active Expired - Fee Related
- 2013-05-03 AU AU2013255470A patent/AU2013255470B2/en not_active Ceased
- 2013-05-03 PL PL13729096T patent/PL2855456T3/pl unknown
- 2013-05-03 WO PCT/IB2013/053546 patent/WO2013164802A1/en not_active Ceased
- 2013-05-03 EP EP13729096.1A patent/EP2855456B1/en active Active
- 2013-05-03 KR KR1020147033713A patent/KR20150003903A/ko not_active Withdrawn
- 2013-05-03 AP AP2014008040A patent/AP2014008040A0/xx unknown
- 2013-05-03 PT PT137290961T patent/PT2855456T/pt unknown
- 2013-05-03 ES ES13729096T patent/ES2630079T3/es active Active
- 2013-05-06 AR ARP130101533A patent/AR090945A1/es unknown
-
2014
- 2014-10-22 TN TN2014000449A patent/TN2014000449A1/fr unknown
- 2014-10-27 IL IL235362A patent/IL235362A0/en unknown
- 2014-10-28 CL CL2014002919A patent/CL2014002919A1/es unknown
- 2014-11-04 PH PH12014502462A patent/PH12014502462A1/en unknown
- 2014-11-04 CR CR20140508A patent/CR20140508A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1206017A1 (en) | 2015-12-31 |
| AU2013255470B2 (en) | 2015-09-17 |
| TN2014000449A1 (en) | 2016-03-30 |
| CR20140508A (es) | 2015-03-13 |
| SG11201406973PA (en) | 2014-12-30 |
| PH12014502462A1 (en) | 2014-12-22 |
| TW201348199A (zh) | 2013-12-01 |
| EA027113B1 (ru) | 2017-06-30 |
| BR112014027359A2 (pt) | 2017-07-18 |
| IL235362A0 (en) | 2014-12-31 |
| WO2013164802A1 (en) | 2013-11-07 |
| CL2014002919A1 (es) | 2015-07-03 |
| AU2013255470A1 (en) | 2014-11-13 |
| EP2855456A1 (en) | 2015-04-08 |
| AP2014008040A0 (en) | 2014-10-31 |
| CN104603127A (zh) | 2015-05-06 |
| EA201492023A1 (ru) | 2015-03-31 |
| JP2015515976A (ja) | 2015-06-04 |
| UY34781A (es) | 2013-12-31 |
| JP6180514B2 (ja) | 2017-08-16 |
| MX2014013428A (es) | 2015-02-04 |
| KR20150003903A (ko) | 2015-01-09 |
| CN104603127B (zh) | 2016-10-05 |
| ES2630079T3 (es) | 2017-08-17 |
| PL2855456T3 (pl) | 2017-09-29 |
| EP2855456B1 (en) | 2017-03-29 |
| PT2855456T (pt) | 2017-07-10 |
| CA2872000A1 (en) | 2013-11-07 |
| PE20150623A1 (es) | 2015-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
| AR113964A1 (es) | Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa | |
| AR112834A1 (es) | Derivados de rapamicina | |
| ES2630079T3 (es) | Moduladores de la ruta del complemento y usos de los mismos | |
| AR094557A1 (es) | Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con deficiencia de smn | |
| AR114254A1 (es) | Moduladores del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso de preparación de los moduladores | |
| AR106472A1 (es) | Inhibidores de acc y usos de los mismos | |
| AR105820A1 (es) | Análogos de nucleósidos sustituidos en el anillo aromático bicíclico 6-6 para su uso como inhibidores de prmt5 | |
| AR088828A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| AR087760A1 (es) | Heterociclilaminas como inhibidores de pi3k | |
| AR087127A1 (es) | Compuestos que se unen a fxr (nr1h4) y modulan su actividad | |
| AR082029A1 (es) | Derivados de heterociclos nitrogenados, composiciones y metodos para modular la via de señalizacion de wnt | |
| AR100033A1 (es) | Compuestos y composiciones para inhibir la actividad de shp2 | |
| AR062011A1 (es) | Derivados de diazol y sus composiciones como inhibidores de itpkb | |
| AR095430A1 (es) | Compuestos de pirimidina y piridina y su uso como inhibidores de la actividad de fgfr | |
| AR088810A1 (es) | Moduladores del receptor mas acoplado a la proteina g utiles en el tratamiento de trastornos cardiovasculares y composiciones farmaceuticas que los contienen | |
| AR093143A1 (es) | Compuestos de 2-aminopiridina | |
| AR100418A1 (es) | Compuestos y composiciones para inducir condrogénesis | |
| AR094790A1 (es) | Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep | |
| AR090293A1 (es) | Inhibidores de quinasa a base de arileter | |
| AR091534A1 (es) | Derivados de sulfonamida y metodos de uso de los mismos para mejorar la farmacocinetica de un farmaco | |
| AR089182A1 (es) | Derivados de aminopirimidina como moduladores de lrrk2 | |
| AR078776A1 (es) | Derivados de (1,1,1,3,3,3-hexafluoro-2-hidroxipropan-2-il)-fenilo | |
| AR112468A1 (es) | Carboxamidas como inhibidores de proteasa específicos de ubiquitina | |
| AR097545A1 (es) | COMPUESTOS A BASE DE PIRAZOLO[1,5-a]PIRIMIDINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |